

# Clint T Allen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/759173/publications.pdf>

Version: 2024-02-01

110  
papers

3,992  
citations

109321

35  
h-index

138484

58  
g-index

112  
all docs

112  
docs citations

112  
times ranked

5586  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 96-107.	0.5	0
2	Determining if T cell antigens are naturally processed and presented on HLA class I molecules. <i>BMC Immunology</i> , 2022, 23, 5.	2.2	4
3	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. <i>JCI Insight</i> , 2022, 7, .	5.0	5
4	Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNF $\pm$ Resistance in Head and Neck Cancers. <i>Molecular Cancer Research</i> , 2022, 20, 867-882.	3.4	5
5	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF- $\beta$ 2 blockade in HPV-unrelated head and neck cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	18
6	Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. <i>Head and Neck</i> , 2022, 44, .	2.0	2
7	The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations. <i>Oral Oncology</i> , 2022, 132, 106012.	1.5	8
8	How Enhancing Immunity to Low-Risk HPV Could Cure Recurrent Respiratory Papillomatosis. <i>Laryngoscope</i> , 2021, 131, 2041-2047.	2.0	9
9	Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. , 2021, 9, e002128.		20
10	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6092-TPS6092.	1.6	2
11	Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. <i>EBioMedicine</i> , 2021, 67, 103345.	6.1	21
12	The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma. <i>Biomarker Research</i> , 2021, 9, 42.	6.8	16
13	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. <i>Npj Vaccines</i> , 2021, 6, 86.	6.0	4
14	Biologics for the Treatment of Recurrent Respiratory Papillomatosis. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 769-777.	1.1	7
15	Dual PD-L1 and TGF- $\beta$ blockade in patients with recurrent respiratory papillomatosis. , 2021, 9, e003113.		12
16	Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. <i>Arthritis and Rheumatology</i> , 2021, 73, 1886-1895.	5.6	125
17	Immunotherapy for HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 361-370.	2.2	5
18	Trismus and voice change after starting tuberculosis treatment. <i>IDCases</i> , 2021, 26, e01307.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages. <i>Cancer Research</i> , 2021, 81, 5977-5990.	0.9	14
20	Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer. <i>Biomarker Research</i> , 2021, 9, 90.	6.8	7
21	Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes. <i>Communications Biology</i> , 2021, 4, 1416.	4.4	10
22	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. <i>Clinical Cancer Research</i> , 2020, 26, 679-689.	7.0	49
23	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. <i>Clinical Cancer Research</i> , 2020, 26, 1420-1431.	7.0	151
24	Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases. <i>JAMA Oncology</i> , 2020, 6, 1967.	7.1	0
25	Antigen processing and presentation in cancer immunotherapy. , 2020, 8, e001111.		66
26	Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 1396-1402.	5.6	24
27	Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer. <i>Head and Neck</i> , 2020, 42, 2722-2733.	2.0	16
28	ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. <i>Oncolimmunology</i> , 2020, 9, 1710398.	4.6	30
29	PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. , 2020, 8, e000450.		79
30	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. <i>ELife</i> , 2020, 9, .	6.0	32
31	Improving responses to immunotherapy in head and neck squamous cell carcinoma. , 2020, , 107-133.		0
32	Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. <i>Oncolimmunology</i> , 2019, 8, e1638207.	4.6	39
33	Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV <sup>-</sup> and HPV <sup>+</sup> Head and Neck Cancers to TNF $\pm$ , TRAIL, and Radiation Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 6463-6474.	7.0	28
34	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. <i>Cancer Immunology Research</i> , 2019, 7, 401-413.	3.4	99
35	Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. <i>Oral Oncology</i> , 2019, 90, 38-44.	1.5	22
36	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35

#	ARTICLE	IF	CITATIONS
37	How patients with an intact immune system develop head and neck cancer. <i>Oral Oncology</i> , 2019, 92, 26-32.	1.5	11
38	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	3.7	127
39	Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. <i>Cancer Immunology Research</i> , 2019, 7, 282-291.	3.4	38
40	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. <i>JCI Insight</i> , 2019, 4, .	5.0	168
41	Galectin-1â€driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5553-5567.	8.2	94
42	Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy. , 2019, , .		0
43	Abstract 3206: Host immunity following near infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established highly antigenic tumors. , 2019, , .		0
44	Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. <i>Head and Neck</i> , 2018, 40, 1321-1334.	2.0	11
45	Nanocomplex-based <i>TP53</i> gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. <i>Oncolmmunology</i> , 2018, 7, e1404216.	4.6	26
46	The PDâ€ and PDâ€L1 pathway in recurrent respiratory papillomatosis. <i>Laryngoscope</i> , 2018, 128, E27-E32.	2.0	31
47	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. <i>Oncolmmunology</i> , 2018, 7, e1395996.	4.6	90
48	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. <i>Oncolmmunology</i> , 2018, 7, e1466018.	4.6	51
49	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. , 2018, 6, 59.		43
50	WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1488359.	4.6	41
51	Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. <i>Oncolmmunology</i> , 2018, 7, e1471440.	4.6	43
52	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 4109-4119.	1.8	34
53	Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy. , 2018, , .		0
54	Inflammation and Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 353-364.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Abstract 3906: Inhibition ofNF-κB Inducing Kinase (NIK) to suppressNF-κB alternative pathway and cell migration in HNSCC. , 2018, , .		0
56	Abstract 1762: Shifting the tumor microenvironment with first-in-class semaphorin 4D mab for combination immunotherapy. , 2018, , .		0
57	Abstract PR09: Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies. , 2018, , .		0
58	Evaluating the utility of serological testing in laryngotracheal stenosis. Laryngoscope, 2017, 127, 1408-1412.	2.0	7
59	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3KÎ³. Cancer Research, 2017, 77, 2607-2619.	0.9	165
60	Laryngotracheal Stenosis: Risk Factors for Tracheostomy Dependence and Dilation Interval. Otolaryngology - Head and Neck Surgery, 2017, 156, 321-328.	1.9	54
61	Murray secretion scale and fiberoptic endoscopic evaluation of swallowing in predicting aspiration in dysphagic patients. European Archives of Oto-Rhino-Laryngology, 2017, 274, 2513-2519.	1.6	24
62	Induction of tumor regression by intratumoral STING agonists combined with antiâ€“programmed deathâ€“1 blocking antibody in a preclinical squamous cell carcinoma model. Head and Neck, 2017, 39, 1086-1094.	2.0	38
63	Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Antiâ€“CD44-Based NIR-PIT. Molecular Cancer Research, 2017, 15, 1667-1677.	3.4	64
64	Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. Cancer Immunology Research, 2017, 5, 1141-1151.	3.4	160
65	Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. Oral Oncology, 2017, 71, 87-94.	1.5	26
66	Office-Based vs Traditional Operating Room Management of Recurrent Respiratory Papillomatosis. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 55.	2.2	13
67	Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays. Journal of Immunological Methods, 2017, 440, 12-18.	1.4	18
68	Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget, 2017, 8, 55804-55820.	1.8	75
69	Abstract 2637: Anti-tumor activity of cisplatin is enhanced by PD-1 blockade in preclinical models of head and neck squamous cell carcinoma. , 2017, , .		0
70	Abstract 3996: MDSC depletion combined with CTLA-4 blockade cause tumor regression in a syngeneic model of oral cavity cancer. , 2017, , .		0
71	Abstract 1696: High-dose versus low-dose fractionated ionizing radiation to enhance antigen-specific antitumor immunity. , 2017, , .		0
72	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncology, 2016, 58, 59-70.	1.5	115

#	ARTICLE	IF	CITATIONS
73	Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. <i>Cancer Immunology Research</i> , 2016, 4, 611-620.	3.4	73
74	Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 1061-1071.	3.4	114
75	Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. <i>Head and Neck</i> , 2016, 38, 1176-1186.	2.0	17
76	Anatomic Derkey Score Is Associated with Voice Handicap in Laryngeal Papillomatosis in Adults. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 689-692.	1.9	16
77	Abstract B087: Cyclic dinucleotide: A novel adjuvant for squamous cell carcinoma. , 2016, , .		0
78	Abstract 1477: Targeting immunosuppressive myeloid cells in oral cavity cancer with the PI3K $\gamma/\delta$ isoform inhibitor duvelisib. , 2016, , .		0
79	Abstract 1448: MDSC depletion delays primary tumor growth in syngeneic models of oral cavity cancer. , 2016, , .		0
80	A Submucosal True Vocal Fold Mass. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 1025.	2.2	2
81	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <i>Cancers</i> , 2015, 7, 2397-2414.	3.7	61
82	Tracheal Mass. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 291.	2.2	4
83	<i>CCR</i> 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 942-943.	7.0	7
84	mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. <i>Oncotarget</i> , 2015, 6, 36400-36417.	1.8	43
85	Immunohistochemical Analysis of NF- $\kappa$ B in Human Tumor Tissue. <i>Methods in Molecular Biology</i> , 2015, 1280, 459-468.	0.9	0
86	Risk stratification in endoscopic airway surgery: is inpatient observation necessary?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2014, 35, 747-752.	1.3	5
87	Hoarseness After Metastatic Colon Cancer Treatment. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 881.	2.2	10
88	Aberrant IKK $\alpha$ and IKK $\beta$ cooperatively activate NF- $\kappa$ B and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. <i>Oncogene</i> , 2014, 33, 1135-1147.	5.9	74
89	Emerging insights into head and neck cancer metastasis. <i>Head and Neck</i> , 2013, 35, 1669-1678.	2.0	53
90	Clinical Assessment and Treatment of the Dysfunctional Larynx after Radiation. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 149, 830-839.	1.9	18

#	ARTICLE	IF	CITATIONS
91	Endoscopic Keel Placement to Treat and Prevent Anterior Glottic Webs. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2013, 122, 672-678.	1.1	24
92	Prevalence of Diabetes Mellitus and Its Impact on Disease Severity in Adult Recurrent Respiratory Papillomatosis. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 149, 603-607.	1.9	5
93	Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 147, 493-500.	1.9	63
94	The clinical implications of antitumor immunity in head and neck cancer. <i>Laryngoscope</i> , 2012, 122, 144-157.	2.0	52
95	Pathology Quiz Case 1. <i>JAMA Otolaryngology</i> , 2011, 137, 526.	1.2	3
96	TNF- $\alpha$ Promotes c-REL/Np63 Interaction and TAp73 Dissociation from Key Genes That Mediate Growth Arrest and Apoptosis in Head and Neck Cancer. <i>Cancer Research</i> , 2011, 71, 6867-6877.	0.9	71
97	Np63 Versatilely Regulates a Broad NF- $\kappa$ B Gene Program and Promotes Squamous Epithelial Proliferation, Migration, and Inflammation. <i>Cancer Research</i> , 2011, 71, 3688-3700.	0.9	119
98	Abstract 5005: Combined targeting of IKK $\alpha$ and $\beta$ effectively suppresses NF- $\kappa$ B activation, cell survival and migration in head and neck squamous cell cancers. , 2011, , .		0
99	Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 447-454.	0.8	33
100	Human papillomavirus and oropharynx cancer: Biology, detection and clinical implications. <i>Laryngoscope</i> , 2010, 120, 1756-1772.	2.0	154
101	Pathology Quiz Case 2. <i>JAMA Otolaryngology</i> , 2010, 136, 311.	1.2	0
102	Abstract 3900: Nuclear c-REL displaces p73 in partnering with DNp63 to suppress p21 expression and promote proliferation in head and neck cancer. , 2010, , .		0
103	Pathology Quiz Case 2. <i>JAMA Otolaryngology</i> , 2009, 135, 1056.	1.2	0
104	Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2361-2372.	7.0	55
105	Bortezomib-Induced Apoptosis with Limited Clinical Response Is Accompanied by Inhibition of Canonical but not Alternative Nuclear Factor- $\kappa$ B Subunits in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4175-4185.	7.0	69
106	Pulsed High-Intensity Focused Ultrasound Enhances Apoptosis and Growth Inhibition of Squamous Cell Carcinoma Xenografts with Proteasome Inhibitor Bortezomib. <i>Radiology</i> , 2008, 248, 485-491.	7.3	56
107	The p53 Homologue Np63 $\beta$ Interacts with the Nuclear Factor- $\kappa$ B Pathway to Modulate Epithelial Cell Growth. <i>Cancer Research</i> , 2008, 68, 5122-5131.	0.9	50
108	Nuclear Factor- $\kappa$ B-Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 3182-3190.	7.0	110

#	ARTICLE	IF	CITATIONS
109	Role of activated nuclear factor- $\kappa$ B in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2007, 29, 959-971.	2.0	99
110	Squamous-cell carcinoma. , 0, , 686-692.		0